QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 16 September 2021Portfolio NewsXilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
- 15 September 2021Portfolio NewsPulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
- Video3 August 2021SV NewsPaul LaViolette describes SV's investment focus
- 3 August 2021Portfolio NewsMestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures
- 27 July 2021Portfolio NewsArtios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
- 22 July 2021SV NewsInternational Biotech looks for M&A booster shot
- 19 July 2021SV NewsSV Health Investors becomes a signatory of the Investing in Women Code signifying it’s commitment to contribute to improving female entrepreneurs’ access to tools, resources and finance.
- 13 July 2021Portfolio NewsBicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
- 6 July 2021Portfolio NewsSitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement
- 22 June 2021Portfolio NewsImbria Pharmaceuticals Announces enrolment of the first 10 patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes
- 22 June 2021Portfolio NewsAlchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
- 22 June 2021Portfolio NewsTRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases